Skip to main content
Premium Trial:

Request an Annual Quote

Newomics Closes $3.9M Series A Round

NEW YORK (GenomeWeb) – Mass spec technology firm Newomics has closed a $3.9 million Series A funding round.

The Berkeley, California-based company closed the round on Wednesday, said Daojing Wang, Newomics' founder and CEO, adding that it surpassed its initial target of $3.5 million. The round was led by the Berkeley Catalyst Fund and the Photon Fund.

According to Wang, the funds will be used to expand the company's management team and complete commercialization of its silicon-based multinozzle emitter array (MEA) technology, which the company said increases the sensitivity and robustness of LC-MS, as well as develop assays based on that technology.

The MEA device consists of a series of multinozzle emitters arranged in a circular array on a silicon chip. The multiple emitters allow for higher-throughput experiments, as each emitter can be interfaced to a separate LC system, which enables rapid sequential or parallel mass spec analyses. The increase in nozzles provides an improvement in sensitivity proportional to the square root of the number of nozzles per emitter.

Wang and his co-founder Pan Mao launched Newomics in 2013 as a spinout from the Lawrence Berkeley National Laboratory, where the two invented the MEA technology.

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.